supp.fit

Coenzyme Q10, Niacin and Riboflavin: study protocols

8 study groups took Coenzyme Q10 together with Niacin and Riboflavin. These are the doses the studies gave. They are not a recommendation.

Coenzyme Q10: what the research found →

Dose per serving from research: Coenzyme Q10

8 study groups in 5 studies say how much Coenzyme Q10 participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 50 mg to 100 mg, 88% of 8 study groups.

Daily doseStudy groups
50 mg to 100 mg
7
100 mg to 250 mg
1

Dose per serving from research: Niacin

8 study groups in 5 studies say how much Niacin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 25 mg to 50 mg, 88% of 8 study groups.

Daily doseStudy groups
25 mg or less
1
25 mg to 50 mg
7

Dose per serving from research: Riboflavin

8 study groups in 5 studies say how much Riboflavin participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 5 mg to 10 mg, 88% of 8 study groups.

Daily doseStudy groups
5 mg to 10 mg
7
10 mg to 25 mg
0
25 mg to 50 mg
0
50 mg to 100 mg
0
100 mg to 250 mg
0
250 mg to 500 mg
1

Commonly used together

1 of 8 study groups took Coenzyme Q10, Niacin and Riboflavin with something else, but nothing that 3 or more different studies gave.

8 study groups

Study
Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial
2015 · Verum (investigational nutritional product) · Adults aged 18–65 of either sex with migraine with or without aura, and at least 3 migraine attacks per month before recruitment
150 mg20 mg400 mg90 days63
Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy
2007 · Group IV (CoRN for 45 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified
100 mg50 mg10 mg45 days—
Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy
2007 · Group V (CoRN for 90 days) · Breast cancer patients undergoing tamoxifen therapy; age and sex not specified
100 mg50 mg10 mg90 days—
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin
2007 · Group IV (CoRN for 45 days) · Breast cancer patients treated with tamoxifen
100 mg50 mg10 mg45 days—
Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin
2007 · Group V (CoRN for 90 days) · Breast cancer patients treated with tamoxifen
100 mg50 mg10 mg90 days—
Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy
2008 · CoRN supplement plus tamoxifen · Breast cancer patients undergoing tamoxifen therapy
100 mg50 mg10 mg——
Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy
2008 · Group IV (CoRN for 45 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported
100 mg50 mg10 mg45 days—
Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy
2008 · Group V (CoRN for 90 days) · Breast cancer patients receiving tamoxifen therapy for more than 1 year; age not reported
100 mg50 mg10 mg90 days—